HK1076251A1 - Anti-ngf antibodies and methods using same - Google Patents

Anti-ngf antibodies and methods using same

Info

Publication number
HK1076251A1
HK1076251A1 HK05110620.2A HK05110620A HK1076251A1 HK 1076251 A1 HK1076251 A1 HK 1076251A1 HK 05110620 A HK05110620 A HK 05110620A HK 1076251 A1 HK1076251 A1 HK 1076251A1
Authority
HK
Hong Kong
Prior art keywords
same
pain
antibodies
methods
ngf antibodies
Prior art date
Application number
HK05110620.2A
Other languages
English (en)
Inventor
David L Shelton
Jaume Pons
Arnon Rosenthal
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32686099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1076251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of HK1076251A1 publication Critical patent/HK1076251A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Environmental Sciences (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
HK05110620.2A 2002-12-24 2005-11-23 Anti-ngf antibodies and methods using same HK1076251A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43690502P 2002-12-24 2002-12-24
US44352203P 2003-01-28 2003-01-28
US51000603P 2003-10-08 2003-10-08
PCT/US2003/041252 WO2004058184A2 (fr) 2002-12-24 2003-12-24 Anticorps anti-ngf et procedes d'utilisation de ces anticorps

Publications (1)

Publication Number Publication Date
HK1076251A1 true HK1076251A1 (en) 2006-01-13

Family

ID=32686099

Family Applications (3)

Application Number Title Priority Date Filing Date
HK05110620.2A HK1076251A1 (en) 2002-12-24 2005-11-23 Anti-ngf antibodies and methods using same
HK08101386.2A HK1110513A1 (en) 2002-12-24 2008-02-05 Anti-ngf antibodies and methods using same
HK13104894.4A HK1177754A1 (zh) 2002-12-24 2013-04-23 抗體及其使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK08101386.2A HK1110513A1 (en) 2002-12-24 2008-02-05 Anti-ngf antibodies and methods using same
HK13104894.4A HK1177754A1 (zh) 2002-12-24 2013-04-23 抗體及其使用方法

Country Status (23)

Country Link
US (6) US7449616B2 (fr)
EP (4) EP1575517B1 (fr)
JP (3) JP4134170B2 (fr)
KR (2) KR101410692B1 (fr)
CN (2) CN101014364B (fr)
AT (1) ATE553128T1 (fr)
AU (1) AU2003299898B2 (fr)
BR (1) BRPI0317738B8 (fr)
CA (3) CA2936742C (fr)
DK (3) DK2263692T3 (fr)
EA (1) EA011479B1 (fr)
ES (3) ES2697876T3 (fr)
HK (3) HK1076251A1 (fr)
HU (1) HUE026089T2 (fr)
IL (3) IL169221A (fr)
MX (1) MXPA05006854A (fr)
NO (2) NO336655B1 (fr)
NZ (2) NZ587852A (fr)
PL (1) PL215171B1 (fr)
PT (3) PT1575517E (fr)
SI (3) SI1575517T1 (fr)
WO (1) WO2004058184A2 (fr)
ZA (1) ZA200504866B (fr)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500901A1 (fr) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Procedes permettant de traiter l'arythmie cardiaque et de prevenir la mort due a l'arythmie cardiaque au moyen d'antagonistes du ngf
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2005000194A2 (fr) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Procedes permettant de traiter des douleurs post-chirurgicales par administration d'un anticorps dirige contre le facteur de croissance neuronal, et compositions contenant cet anticorps
AU2003285864C1 (en) * 2002-10-08 2010-07-01 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
NZ587852A (en) 2002-12-24 2012-02-24 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
KR20050111598A (ko) * 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
TWI635096B (zh) * 2003-07-15 2018-09-11 安美基公司 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
WO2005062955A2 (fr) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Anticorps anti-trkc agonistes et procedes d'utilisation
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
PL1732949T3 (pl) * 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
JP5042828B2 (ja) 2004-07-30 2012-10-03 ライナット ニューロサイエンス コーポレイション アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
EP2298345A3 (fr) 2005-01-24 2012-03-21 MedImmune Limited Éléments de liaison spécifiques pour NGF
EP1870459B1 (fr) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Procede pour la production de polypeptide au moyen de la regulation d'un ensemble
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
AU2006272713A1 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-CD26 antibodies and methods of use thereof
WO2007035906A2 (fr) 2005-09-21 2007-03-29 The Regents Of The University Of California Systemes, compositions et procedes pour representer localement et traiter la douleur
PL2380592T3 (pl) 2005-11-14 2018-07-31 Teva Pharmaceuticals International Gmbh Przeciwciało antagonistyczne skierowane przeciwko peptydowi powiązanemu z genem kalcytoniny
EP2009101B1 (fr) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Procede de modification d'anticorps pour purifier un anticorps bispecifique
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
AU2012216653B2 (en) * 2007-08-10 2013-12-12 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
ME02239B (fr) * 2007-08-10 2015-04-30 Regeneron Pharma Anticorps humains anti-facteur de croissance nerveux humain de haute affinité
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
EP2197491A4 (fr) * 2007-09-04 2011-01-12 Univ California Anticorps d'antigène de cellule souche anti-prostate (psca) à haute affinité pour un ciblage et une détection de cancer
MY180713A (en) * 2007-09-26 2020-12-07 Chugai Pharmaceutical Co Ltd Modified antibody constant region
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR101499278B1 (ko) * 2007-12-17 2015-03-06 화이자 리미티드 간질성 방광염의 치료
EP2282769A4 (fr) 2008-04-29 2012-04-25 Abbott Lab Immunoglobulines à double domaine variable et utilisations
KR20110016959A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
WO2009150623A1 (fr) 2008-06-13 2009-12-17 Pfizer Inc Traitement de la prostatite chronique
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
WO2010029497A1 (fr) * 2008-09-12 2010-03-18 Pfizer Limited Traitement de l’endométriose
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
EP2166358A1 (fr) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Biomarqueurs de diagnostic différentiel de conditions simulant l'accident vasculaire cérébral et ses procédés d'utilisation
CA2736864C (fr) * 2008-09-19 2020-10-13 Pfizer Inc. Composition, liquide et stable, a base d'anticorps
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US9040508B2 (en) * 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
WO2010086828A2 (fr) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Anticorps monoclonaux agonistes anti-trkb
US20110105951A1 (en) * 2009-10-30 2011-05-05 Seventh Sense Biosystems, Inc. Systems and methods for treating, sanitizing, and/or shielding the skin or devices applied to the skin
JP6078230B2 (ja) 2009-03-02 2017-02-08 セブンス センス バイオシステムズ，インコーポレーテッド 血液サンプリングに関連する技術および装置
WO2012018486A2 (fr) 2010-07-26 2012-02-09 Seventh Sense Biosystems, Inc. Distribution et/ou réception rapide de fluides
DK2448970T3 (da) 2009-05-04 2014-10-06 Abbvie Res B V Antistoffer mod nervevækstfaktor (ngf) med forbedret in vivo-stabilitet
WO2010146511A1 (fr) 2009-06-17 2010-12-23 Pfizer Limited Traitement d'une vessie hyperactive
RU2011151287A (ru) 2009-06-18 2013-07-27 Пфайзер Инк. АНТИ Notch-1 АНТИТЕЛА
US8586714B2 (en) * 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
CA2775959A1 (fr) * 2009-10-15 2011-04-21 Abbott Laboratories Immunoglobulines a deux domaines variables et utilisations afferentes
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011094573A1 (fr) 2010-01-28 2011-08-04 Seventh Sense Biosystems, Inc. Systèmes et procédés de surveillance ou de rétroaction
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
LT2542257T (lt) 2010-03-01 2017-11-27 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
JP2013522313A (ja) 2010-03-17 2013-06-13 アボツト・リサーチ・ベー・フエー 抗神経成長因子（ｎｇｆ）抗体組成物
WO2011163347A2 (fr) * 2010-06-23 2011-12-29 Seventh Sense Biosystems, Inc. Dispositifs et procédés d'échantillonnage entraînant peu de douleur
CN103068308B (zh) 2010-07-16 2016-03-16 第七感生物系统有限公司 用于流体传输装置的低压环境
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012021801A2 (fr) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systèmes et procédés adaptés pour surveiller des sujets
AU2015258217A1 (en) * 2010-08-19 2015-12-03 Zoetis Belgium S.A. Anti-NGF antibodies and their use
LT3333188T (lt) * 2010-08-19 2022-06-10 Zoetis Belgium S.A. Anti-ngf antikūnai ir jų panaudojimas
CN103260639A (zh) * 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
CN103370007B (zh) 2010-11-09 2018-12-18 第七感生物系统有限公司 用于采血的系统和界面
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
JP6016800B2 (ja) 2010-12-15 2016-10-26 ワイス・エルエルシー 抗ノッチ１抗体
JP2014506259A (ja) * 2011-01-17 2014-03-13 ノヴォ ノルディスク アー／エス Ｉｌ−２１リガンド
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
CA2833275C (fr) 2011-04-29 2021-06-15 Seventh Sense Biosystems, Inc. Distribution ou reception de fluides corporels
CN103874461B (zh) 2011-04-29 2017-05-10 第七感生物系统有限公司 收集和/或操纵血斑或其他体液的装置
EP3106092A3 (fr) 2011-04-29 2017-03-08 Seventh Sense Biosystems, Inc. Systèmes et procédés pour recueillir un fluide provenant d'un sujet
CN108424452B (zh) 2011-05-20 2021-08-03 H.伦德贝克公司 抗cgrp组合物及其用途
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
WO2013009582A1 (fr) 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions en contenant et méthodes associées
LT2743348T (lt) 2011-08-11 2018-05-10 Astellas Pharma Inc. Naujas žmogaus anti-naf antikūnas
CA2954166A1 (fr) 2011-11-11 2013-05-16 Rinat Neuroscience Corp. Anticorps specifiques de trop-2 et leurs utilisations
WO2013093693A1 (fr) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Anticorps spécifiques de staphylococcus aureus et leurs utilisations
RU2014123030A (ru) 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
EP2797955A2 (fr) 2011-12-30 2014-11-05 AbbVie Inc. Immunoglobulines à double domaine variable contre contre il-13 et/ou il-17
US9386657B2 (en) 2012-03-15 2016-07-05 Universal Display Corporation Organic Electroluminescent materials and devices
CN104364264B (zh) 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
RU2015115956A (ru) 2012-11-09 2017-01-10 Пфайзер Инк. Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
EP2970459A2 (fr) 2013-03-15 2016-01-20 AbbVie Inc. Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1beta et il -17
CN105189560A (zh) 2013-05-07 2015-12-23 瑞纳神经科学公司 抗胰高血糖素受体抗体和其使用方法
PE20160671A1 (es) 2013-08-02 2016-07-09 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
SG10201810298VA (en) 2013-11-13 2018-12-28 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
WO2015109212A1 (fr) 2014-01-17 2015-07-23 Pfizer Inc. Anticorps anti-il-2 et compositions et utilisations de ceux-ci
DK3102555T3 (da) 2014-02-05 2021-08-09 VM Oncology LLC Sammensætninger af forbindelser og anvendelser deraf
WO2015143409A1 (fr) 2014-03-21 2015-09-24 Labrys Biologics, Inc. Anticorps antagonistes dirigés contre le peptide lié au gène de la calcitonine et leurs procédés d'utilisation
WO2015143653A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143654A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143652A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
TW202339800A (zh) 2015-02-27 2023-10-16 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2016161572A1 (fr) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et procédés associés
CA3219684A1 (fr) 2015-04-13 2016-10-13 Pfizer Inc. Anticorps anti-bcma, anticorps, anti-cd3 et anticorps bispecifiques se liant a bcma et a cd3
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
JP6700620B2 (ja) 2015-05-22 2020-05-27 アステラス製薬株式会社 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3325010B1 (fr) 2015-07-23 2023-06-21 The Regents of The University of California Anticorps anti-facteur de coagulation xia et leurs utilisations
NZ739871A (en) 2015-08-19 2022-05-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
CN108137655B (zh) 2015-09-28 2022-04-22 北卡罗来纳-查佩尔山大学 逃避抗体的病毒载体的方法和组合物
NZ741404A (en) 2015-10-23 2024-03-22 Univ California Anti-il-2 antibodies and compositions and uses thereof
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
CN109219618B (zh) 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
AU2017257330A1 (en) 2016-04-27 2018-10-18 Pfizer Inc. Anti-IL-33 antibodies, compositions, methods and uses thereof
US10829553B2 (en) 2016-04-29 2020-11-10 Pfizer Inc. Interferon beta antibodies and uses thereof
CA3026490A1 (fr) 2016-06-09 2017-12-14 University Of Leicester Anticorps monoclonaux, compositions et methodes de detection de la proteine de type mucine (mlp) en tant que biomarqueur du cancer de l'ovaire et du pancreas
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CA3037661A1 (fr) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Traitement de l'algie vasculaire de la face
BR112019005823A2 (pt) 2016-09-23 2019-06-25 Teva Pharmaceuticals Int Gmbh tratamento para enxaqueca refratária
US11905331B2 (en) 2016-11-11 2024-02-20 Kumho Ht, Inc. Antibody binding specifically to CD40 and use thereof
MA45890B2 (fr) 2016-11-29 2022-10-31 Regeneron Pharma Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
PE20191487A1 (es) 2017-03-03 2019-10-18 Rinat Neuroscience Corp Anticuerpos anti-gitr y metodos de uso de los mismos
US20230192839A1 (en) 2017-04-12 2023-06-22 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
KR102505349B1 (ko) 2017-06-02 2023-03-02 화이자 인코포레이티드 Flt3에 특이적인 항체 및 이의 용도
JP7270557B2 (ja) 2017-06-09 2023-05-10 ファイザー・インク 抗ｒｏｂｏ２抗体、組成物、方法、およびその使用
WO2019018647A1 (fr) 2017-07-20 2019-01-24 Pfizer Inc. Anticorps anti-gd3 et conjugués anticorps-médicament
PE20210554A1 (es) 2017-12-01 2021-03-17 Pfizer Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
CN108059676B (zh) * 2017-12-28 2020-07-31 未名生物医药有限公司 一种抗人神经生长因子scFv抗体及制备方法
PE20210708A1 (es) 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
US10982002B2 (en) 2018-03-12 2021-04-20 Zoetis Services Llc Anti-NGF antibodies and methods thereof
CN112119090B (zh) 2018-03-15 2023-01-13 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
US20210363191A1 (en) 2018-04-03 2021-11-25 Stridebio, Inc. Antibody-evading virus vectors
CN108623687A (zh) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
JPWO2019221097A1 (ja) 2018-05-15 2021-05-27 アステラス製薬株式会社 抗ヒトｎｇｆ抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物
AU2019274655B2 (en) 2018-05-23 2023-03-09 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
US11434292B2 (en) 2018-05-23 2022-09-06 Pfizer Inc. Antibodies specific for CD3 and uses thereof
MX2021001549A (es) 2018-08-10 2021-04-13 Regeneron Pharma Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
US11566066B2 (en) 2018-08-20 2023-01-31 Pfizer Inc. Anti-GDF15 antibodies, compositions and methods of use
BR112021004287A2 (pt) 2018-09-07 2021-08-03 Pfizer Inc. anticorpos anti-avss8 e composições e usos dos mesmos
WO2020146527A1 (fr) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
JP2022518796A (ja) 2019-01-28 2022-03-16 メイプル バイオテック エルエルシー 肺、腎臓、または肝臓の線維症疾患の処置に使用するためのｐｓｍｐアンタゴニスト
JP2020117502A (ja) 2019-01-28 2020-08-06 ファイザー・インク 変形性関節症の徴候および症状を処置する方法
EP3927430A1 (fr) 2019-02-18 2021-12-29 Pfizer Inc. Procédé de traitement de la lombalgie chronique
BR112021018776A2 (pt) 2019-03-21 2021-11-30 Stridebio Inc Vetores de vírus adenoassociado recombinante
WO2020248942A1 (fr) * 2019-06-10 2020-12-17 山东博安生物技术有限公司 NANOCORPS ANTI-β-NGF ET UTILISATION ASSOCIÉE
US20220314142A1 (en) 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
JP2022552323A (ja) 2019-10-15 2022-12-15 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
TW202128736A (zh) 2019-10-17 2021-08-01 美商史崔德生物公司 用於治療ｃ型尼曼—匹克病之腺相關病毒載體
TW202136777A (zh) 2019-12-20 2021-10-01 美商輝瑞股份有限公司 內毒素偵測
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
WO2021205325A1 (fr) 2020-04-08 2021-10-14 Pfizer Inc. Anticorps anti-gucy2c et leurs utilisations
CN117186219A (zh) 2020-04-17 2023-12-08 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
EP4157881A1 (fr) 2020-05-27 2023-04-05 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Anticorps reconnaissant de manière spécifique le facteur de croissance nerveuse et leurs utilisations
PE20231565A1 (es) 2020-07-17 2023-10-04 Pfizer Anticuerpos terapeuticos y sus usos
AU2022223409A1 (en) 2021-02-19 2023-09-21 Theripion, Inc. Dnase fusion polypeptides and related compositions and methods
WO2022195504A1 (fr) 2021-03-19 2022-09-22 Pfizer Inc. Méthode de traitement de la douleur due à l'arthrose avec un anticorps anti-ngf
MX2023013165A (es) 2021-05-12 2023-11-30 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a rankl y ngf, y su uso medico.
WO2023007374A1 (fr) 2021-07-27 2023-02-02 Pfizer Inc. Méthode de traitement de la douleur liée au cancer à l'aide de tanézumab
WO2023079430A1 (fr) 2021-11-02 2023-05-11 Pfizer Inc. Méthodes de traitement de myopathies mitochondriales à l'aide d'anticorps anti-gdf15
WO2023092052A1 (fr) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Méthodes et compositions pour réduire la douleur centralisée
WO2023097275A1 (fr) * 2021-11-23 2023-06-01 Invetx, Inc. Anticorps anti-ngf et leurs utilisations
WO2023212586A1 (fr) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Procédés de sélection de patients pour le traitement avec un antagoniste du ngf
WO2024104409A1 (fr) * 2022-11-16 2024-05-23 苏州盛迪亚生物医药有限公司 Composition pharmaceutique comprenant des anticorps bispécifiques anti-rankl-ngf

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4013556A (en) * 1976-08-19 1977-03-22 Uop Inc. Combination flow distribution and collection apparatus
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
SU975016A1 (ru) 1979-12-17 1982-11-23 Московский научно-исследовательский онкологический институт им.П.А.Герцена Болеутол ющее средство
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544045A (en) * 1983-04-01 1985-10-01 Allied Corporation Mechanical actuator for a disc brake
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4574065A (en) * 1983-12-21 1986-03-04 Armstrong World Industries, Inc. Non-directional floor tile
US4663195A (en) * 1984-08-15 1987-05-05 Nordson Corporation Continuous coating process for discrete articles
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1989009225A1 (fr) 1988-03-28 1989-10-05 The Regents Of The University Of California Peptides du facteur de croissance des neurones du systeme nerveux peripherique
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (fr) 1989-01-23 1990-07-26 Chiron Corporation Therapies de recombinaison pour infections et troubles hyperproliferatifs
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
WO1991000360A1 (fr) 1989-06-29 1991-01-10 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
EP0845537A1 (fr) 1989-08-18 1998-06-03 Chiron Corporation Retrovirus recombinants exprimant une pro-drogue pour le traitement des GVhD
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JPH03163095A (ja) 1989-08-28 1991-07-15 Takeda Chem Ind Ltd ヒト神経成長因子の部分ペプチド、抗体およびその用途
DK0418590T3 (da) 1989-08-28 1998-04-20 Takeda Chemical Industries Ltd Antistoffer, fremstilling deraf og anvendelse deraf
US5656435A (en) 1989-08-28 1997-08-12 Takeda Chemical Industries, Ltd. Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2654332B1 (fr) * 1989-11-13 1997-11-21 Biotrol Sa Lab Appareillage pour stomie.
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0814159B1 (fr) 1990-08-29 2005-07-27 GenPharm International, Inc. Souris transgéniques capables de produire des anticorps hétérologues
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06317587A (ja) 1990-08-31 1994-11-15 Takeda Chem Ind Ltd 抗体およびその用途
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
EP0485927A1 (fr) * 1990-11-16 1992-05-20 Hoechst Aktiengesellschaft Acides sulfimidoperoxycarboxyliques
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
CA2102511A1 (fr) 1991-05-14 1992-11-15 Paul J. Higgins Anticorps heteroconjugues pour le traitement de l'infection a vih
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5210671A (en) * 1991-08-29 1993-05-11 Verbatim Corporation Write protection for memory diskettes
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
JPH0576384A (ja) 1991-09-20 1993-03-30 Hitachi Ltd 抗ヒト神経成長因子モノクローナル抗体
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0605522B1 (fr) 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
WO1993010218A1 (fr) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5180370A (en) * 1992-05-18 1993-01-19 Gillespie Elgene R Safety hypodermic syringe with retractable needle
WO1993025234A1 (fr) 1992-06-08 1993-12-23 The Regents Of The University Of California Procedes et compositions permettant de cibler des tissus specifiques
US5342942A (en) 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
CA2137361A1 (fr) 1992-06-10 1993-12-23 W. French Anderson Vecteurs particulaires resistants a l'inactivation par le serum humain
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP0673431A1 (fr) 1992-12-03 1995-09-27 Genzyme Corporation Therapie genique de la fibrose kystique
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
DK0695169T3 (da) 1993-04-22 2003-03-17 Skyepharma Inc Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse
IT1264456B1 (it) * 1993-05-14 1996-09-23 Dompe Farmaceutici Spa Derivati del 2-(benzimidazol-2-il)-1,3-diaminopropano farmacologicamente attivi.
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
ES2328424T3 (es) 1993-09-15 2009-11-12 Novartis Vaccines And Diagnostics, Inc. Vectores de alfavirus recombinantes.
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
PT729351E (pt) 1993-11-16 2000-12-29 Skyepharma Inc Vesiculas com libertacao controlada de activos
WO1995014776A1 (fr) 1993-11-23 1995-06-01 Genentech, Inc. TYROSINE KINASES PROTEIQUES APPELEES Rse
US6025145A (en) 1993-11-23 2000-02-15 Genentech, Inc. Kinase receptor activation assay
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
ATE381624T1 (de) 1994-05-09 2008-01-15 Oxford Biomedica Ltd Retrovirale vektoren mit verminderter rekombinationsrate
US6291247B1 (en) 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
GB9514160D0 (en) 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU3695295A (en) 1995-10-25 1997-05-15 Queen's University At Kingston Neurotrophin antagonists
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
EP0953052B1 (fr) 1996-05-06 2009-03-04 Oxford BioMedica (UK) Limited Vecteurs retroviraux sans croisement
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
CA2268450C (fr) 1996-10-21 2008-08-05 Allelix Biopharmaceuticals, Inc. Compositions antagonistes de la neurotrophine
EP1829539A3 (fr) 1996-11-05 2008-02-20 HEADEXPLORER ApS Procédé de traitement de cephalees du type par tension nerveuse
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
CN1122304C (zh) * 1997-02-10 2003-09-24 松下电器产业株式会社 树脂封装型半导体装置的制造方法
FR2759720B1 (fr) * 1997-02-19 1999-04-30 Degremont Procede de realisation d'un plancher de filtre pour le traitement des eaux
DE19732928C2 (de) 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
US5981650A (en) * 1997-08-26 1999-11-09 Ashland Inc. Cold seal adhesives, cold sealable films and packages formed therewith
WO1999018792A1 (fr) 1997-10-10 1999-04-22 Johns Hopkins University Compositions et procedes d'apport de genes
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9807781D0 (en) 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
CN1228995A (zh) * 1999-01-26 1999-09-22 卢杲 一种治疗老年性痴呆症、帕金森症、心脑血管病的药物
EP1158997A2 (fr) 1999-03-09 2001-12-05 University Of Southern California Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
EP1265605B1 (fr) 2000-01-18 2006-09-27 McGILL UNIVERSITY Compositions pharmaceutiques comprenant des composes cycliques peptidomimetiques a coude beta
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
JP4901051B2 (ja) 2000-05-30 2012-03-21 ジョンソン アンド ジョンソン リサーチ プロプライアトリー リミテッド ＲＮＡｉを増強する因子を使用することによって遺伝子抑制を媒介する方法
US7022484B2 (en) 2000-06-08 2006-04-04 Board Of Regents, The University Of Texas System Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
GB0020504D0 (en) 2000-08-18 2000-10-11 Univ Bristol Therapeutic method
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
EP1339680A1 (fr) 2000-09-01 2003-09-03 Glaxo Group Limited Derives d'oxindole substitues utilises comme inhibiteurs de la tyrosine kinase
US6964977B2 (en) 2000-09-01 2005-11-15 Smithkline Beecham Corporation Oxindole derivatives
EP1873259B1 (fr) 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interférence ARN à médiation par ARN 21 et 22nt
EP2340849A1 (fr) 2001-05-30 2011-07-06 Genentech, Inc. Anticorps anti-NGF pour le traitement de diverses maladies
WO2002102232A2 (fr) 2001-06-14 2002-12-27 The Regents Of The University Of California Nouvelle voie de signalisation destinee a la production de douleur inflammatoire et de neuropathie
US7288246B2 (en) 2001-09-13 2007-10-30 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral glutaminase regulation
EP1517921B1 (fr) * 2002-06-28 2006-06-07 Domantis Limited Ligands a specificite double et avec une demi-vie augmentee
US20040038874A1 (en) 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain
AU2003294221A1 (en) 2002-09-13 2004-04-19 Kenneth E. Miller Method of alleviating pain via inhibition of neurotransmitter synthesis
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
CA2500901A1 (fr) 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Procedes permettant de traiter l'arythmie cardiaque et de prevenir la mort due a l'arythmie cardiaque au moyen d'antagonistes du ngf
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003285864C1 (en) 2002-10-08 2010-07-01 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
WO2005000194A2 (fr) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Procedes permettant de traiter des douleurs post-chirurgicales par administration d'un anticorps dirige contre le facteur de croissance neuronal, et compositions contenant cet anticorps
JP3818255B2 (ja) 2002-12-16 2006-09-06 住友電気工業株式会社 端部に回折光学膜を有する光ファイバとその製造方法
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
NZ587852A (en) * 2002-12-24 2012-02-24 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US20060147932A1 (en) 2003-01-18 2006-07-06 Alun Davies Methods of screening for modulators of nerve growth factor
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
JP3923028B2 (ja) 2003-04-28 2007-05-30 シャープ株式会社 画像記録システム及び画像記録装置
TWI635096B (zh) * 2003-07-15 2018-09-11 安美基公司 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
PL1732949T3 (pl) 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
EP2298345A3 (fr) 2005-01-24 2012-03-21 MedImmune Limited Éléments de liaison spécifiques pour NGF
ME02239B (fr) * 2007-08-10 2015-04-30 Regeneron Pharma Anticorps humains anti-facteur de croissance nerveux humain de haute affinité
CA2736864C (fr) 2008-09-19 2020-10-13 Pfizer Inc. Composition, liquide et stable, a base d'anticorps
DK2448970T3 (da) 2009-05-04 2014-10-06 Abbvie Res B V Antistoffer mod nervevækstfaktor (ngf) med forbedret in vivo-stabilitet
LT3333188T (lt) * 2010-08-19 2022-06-10 Zoetis Belgium S.A. Anti-ngf antikūnai ir jų panaudojimas
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
CN104364264B (zh) * 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法

Also Published As

Publication number Publication date
ES2697876T3 (es) 2019-01-29
US8088384B2 (en) 2012-01-03
WO2004058184A3 (fr) 2006-07-27
US7449616B2 (en) 2008-11-11
SI1575517T1 (sl) 2012-06-29
EP2270048A2 (fr) 2011-01-05
PL380679A1 (pl) 2007-03-05
EP2263692A1 (fr) 2010-12-22
AU2003299898A1 (en) 2004-07-22
CN101014364A (zh) 2007-08-08
NO20053583L (no) 2005-09-23
AU2003299898B2 (en) 2010-12-16
JP4134170B2 (ja) 2008-08-13
ZA200504866B (en) 2006-11-29
CN102746399A (zh) 2012-10-24
CA2936742A1 (fr) 2004-07-15
KR20120128699A (ko) 2012-11-27
EP2263692B1 (fr) 2018-09-19
US9708398B2 (en) 2017-07-18
KR101410692B1 (ko) 2014-06-24
EA200501043A1 (ru) 2006-06-30
US11008386B2 (en) 2021-05-18
PT2270048E (pt) 2016-02-10
CA2511598C (fr) 2016-09-13
HK1177754A1 (zh) 2013-08-30
KR20050096101A (ko) 2005-10-05
ES2564752T3 (es) 2016-03-28
EP2270048A3 (fr) 2011-03-02
US9212222B2 (en) 2015-12-15
BRPI0317738B1 (pt) 2018-01-16
CA2936742C (fr) 2020-05-26
JP4336728B2 (ja) 2009-09-30
PL215171B1 (pl) 2013-10-31
KR101250818B1 (ko) 2013-04-15
PT2263692T (pt) 2018-11-28
JP2009159977A (ja) 2009-07-23
JP2006525955A (ja) 2006-11-16
IL169221A (en) 2012-03-29
ATE553128T1 (de) 2012-04-15
EP3539569A1 (fr) 2019-09-18
ES2382918T3 (es) 2012-06-14
NZ540730A (en) 2010-09-30
US7655232B2 (en) 2010-02-02
CA2921578C (fr) 2017-02-14
NO336655B1 (no) 2015-10-12
US20170342143A1 (en) 2017-11-30
NZ587852A (en) 2012-02-24
IL263573A (en) 2019-01-31
EP1575517B1 (fr) 2012-04-11
HK1110513A1 (en) 2008-07-18
CN102746399B (zh) 2016-03-02
NO339595B1 (no) 2017-01-09
CA2921578A1 (fr) 2004-07-15
NO20053583D0 (no) 2005-07-22
US20040237124A1 (en) 2004-11-25
DK2263692T3 (da) 2018-11-26
US20160152698A1 (en) 2016-06-02
EP2270048B1 (fr) 2015-11-11
HUE026089T2 (hu) 2016-05-30
JP2008148710A (ja) 2008-07-03
EP1575517A4 (fr) 2007-10-24
US20100111970A1 (en) 2010-05-06
US20150050286A1 (en) 2015-02-19
EP1575517A2 (fr) 2005-09-21
MXPA05006854A (es) 2005-12-12
SI2263692T1 (sl) 2020-10-30
US20070212357A1 (en) 2007-09-13
BRPI0317738B8 (pt) 2021-05-25
DK1575517T3 (da) 2012-05-14
DK2270048T3 (en) 2016-01-18
IL218087A0 (en) 2012-03-29
EA011479B1 (ru) 2009-04-28
BR0317738A (pt) 2005-11-22
SI2270048T1 (sl) 2016-01-29
PT1575517E (pt) 2012-05-28
IL218087B (en) 2019-09-26
NO20150469L (no) 2005-09-23
WO2004058184A2 (fr) 2004-07-15
CA2511598A1 (fr) 2004-07-15
CN101014364B (zh) 2012-01-18

Similar Documents

Publication Publication Date Title
IL263573A (en) Anti-ngf antibodies and methods of using them
TW200716672A (en) Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
EP1635822A4 (fr) Methodes et compositions de traitement de polyarthrite rhumatoide
TW200631594A (en) Toll like receptor 3 antagonists, methods and uses
EG24978A (en) Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment.
DK1814878T3 (da) Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf
WO2005000194A3 (fr) Procedes permettant de traiter des douleurs post-chirurgicales par administration d'un anticorps dirige contre le facteur de croissance neuronal, et compositions contenant cet anticorps
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
WO2004006834A3 (fr) Analogues de leflunomide pour traiter l'arthrite rhumatoide
SI1545537T1 (sl) Agonisti alfa-7 nikoninskega receptorja in statini v kombinaciji
WO2005023201A3 (fr) Methodes de traitement de la polyarthrite rhumatoide
WO2003070904A3 (fr) Ribonuclease iii humaine, compositions et utilisations
WO2002002630A3 (fr) Nouvelles utilisations
AU2002368150A8 (en) Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
SG166768A1 (en) Agonist anti-trkc antibodies and methods using same
WO2006058073A3 (fr) Compositions pharmaceutiques renfermant un inhibiteur selectif de la cox-2 et un diuretique
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
TW200501951A (en) Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
UA49490A (uk) Спосіб лікування ревматоїдного артриту
AU2003259028A1 (en) Combinations for the treatment of rheumatoid arthritis
ZA200304435B (en) Method of mineral treatment.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231223